# A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

> **NCT05182944** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 130 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** A：non-pCR patients
- **DRUG:** B：non-pCR patients
- **DRUG:** A：pCR patients
- **DRUG:** B：pCR patients

## Key facts

- **NCT ID:** NCT05182944
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-15
- **Primary completion:** 2024-01-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182944, "A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05182944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*